PubMed HealthSearch

PubMed · 7571856

[Tuberculosis: current epidemiological-clinical problems].

Abstract

Tuberculosis (tb) mortality, morbidity and infection prevalence were very high in Belgium and in the other industrialised countries during the previous century, and the first half of this century. Therefore tb was an "export" pathology, especially towards developing countries. At the end of this century tb-epidemiological indices reached very low levels in the Western world, while tb became endemic in several non-Western countries and so it actually has become an "import" pathology. In the USA, as well as in many European countries, the tb-morbidity incidence started to increase again about ten years ago. The risk groups are, however, not identical in the USA and in Belgium. In the USA, it is particularly the AIDS-epidemic that is the cause of half of the increase in tb-incidence; in addition social outcasts, homeless and IV-drug addicts are important risk groups and due to their poor therapy compliance they are responsible for the many multidrug resistant forms emerging in New York and other large cities. In Belgium elderly males are an important risk group with a tb-incidence of 50 per 10(5) in 1993 (versus an overall incidence of 15 per 10(5)). Besides, in this group the diagnosis is often made late. A second important risk group consists of allochthones, with an incidence of 54 per 10(5), especially non-Western allochthones, with an incidence of 120 per 10(5). Above all others are the asylum seekers with an estimated incidence of 400 per 10(5) (which undoubtedly is an underestimation). In Belgium, the AIDS-epidemic does not represent a major problem so far; only 3.5% of the tb-cases have AIDS or are HIV-positive, and 50% of these are immigrants. Finally, also multidrug resistance is no real problem, since resistance against isoniazide and rifampicin has been found in only 0.5% of the tb-cases. Contact persons of tb-cases, however, still remain a very important risk group with an incidence of more than 200 per 10(5). The danger is especially great for as long as the diagnosis has not been made in the source of infection and no therapeutic measures have been taken. While the overall tb-threat increased in the last decade, the tb-organisations (in Flanders the VRGT, Vereniging voor Respiratoire Gezondheidszorg en Tuberculosebestrijding) have been more or less dismantled, which in consequence may lead to problems in the future!(ABSTRACT TRUNCATED AT 400 WORDS)

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Demedts, P Van den Brande, A Gyselen. 1995. [Tuberculosis: current epidemiological-clinical problems].. https://pubmed.ncbi.nlm.nih.gov/7571856/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Gastrointestinal manifestations of HIV infection.

The harrowing picture of emaciated terminally ill AIDS patients is a reminder of our lack of understanding of immunological mechanisms that normally control opportunistic infections. Many gastrointestinal pathogens in patients with AIDS are resistant to treatment and lead inexorably to weight loss and death. Although knowledge of the pathogenesis and clinical significance of weight loss has improved considerably, this has not yet led to a sustained effort to improve nutritional status during early stages of disease.

AIDS-Related Opportunistic Infections

A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.

BACKGROUND: Bacteremia with the Mycobacterium avium complex is common in patients with the acquired immunodeficiency syndrome (AIDS), but the most effective treatment for this infection remains unclear. METHODS: We randomly assigned 229 patients with AIDS and M. avium complex bacteremia to receive either rifampin (600 mg daily), ethambutol (approximately 15 mg per kilogram of body weight daily), clofazimine (100 mg daily), and ciprofloxacin (750 mg twice daily) (the four-drug group) or rifabutin (600 mg daily), ethambutol (as above), and clarithromycin (1000 mg twice daily) (the three-drug group). In the three-drug group the dose of rifabutin was reduced by half after 125 patients were randomized, because 24 of 63 patients had uveitis. RESULTS: Among 187 patients who could be evaluated, blood cultures became negative more often in the three-drug group than in the four-drug group (69 percent vs. 29 percent, P<0.001). Among patients treated for at least four weeks, the bacteremia resolved more frequently in the three-drug group (78 percent vs. 40 percent, P<0.001). In the three-drug group, bacteremia resolved more often with the 600-mg dose of rifabutin than with the 300-mg dose (P=0.025), but the latter regimen was more effective than the four-drug regimen (P<0.05). The median survival was 8.6 months in the three-drug group and 5.2 months in the four-drug group (P = 0.001). The median Karnofsky performance score was higher in the three-drug group than in the four-drug group from week 2 to week 16 (P<0.05). Mild uveitis developed in 3 of the 53 patients receiving the 300-mg dose of rifabutin, an incidence about one quarter that observed with the 600-mg dose (P<0.001). CONCLUSIONS: In patients with AIDS and M. avium complex bacteremia, treatment with the three-drug regimen of rifabutin, ethambutol, and clarithromycin leads to resolution of the bacteremia more frequently and more rapidly than treatment with rifampin, ethambutol, clofazimine, and ciprofloxacin, and survival rates are better.

AIDS-Related Opportunistic Infections